“PFA has generated much excitement in the treatment of atrial fibrillation due to an improved safety profile and procedural workflow. However, most of the first generation PFA technologies today are repurposed from other applications and suffer from significant limitations outside a subset of [atrial fibrillation] AFib procedures,” said Steven Mickelsen, CEO, Field Medical. “This collaboration brings together second generation focal PFA and [artificial intelligence] AI-based cardiac mapping—a combination set to revolutionise catheter ablation across the full spectrum of treatable arrhythmias.”
This new collaboration will accelerate development of novel integrated solutions aimed at improving safety and efficacy while minimising need for x-rays used in cardiac catheter ablation, a market that has grown to US$6 billion per year globally. Accurate navigation is critical to the heart rhythm treatment especially outside the atria where magnetic localisation can dramatically improve positioning during the treatment of life threatening ventricular tachycardia.
“We are excited to collaborate with Field Medical to build a purpose-built system from the ground up that incorporates PFA, Contact Force Sensing, Electromagnetic Localisation, and AI-enabled mapping capabilities,” said Jerome Edwards, CEO, CardioNXT. “We believe this will create a first of its kind completely integrated total solution to identify sources of cardiac arrhythmias and deliver therapy to those targets more efficaciously than ever before.”